Genomic and proteomic analyses of vascular endothelial growth factor and insulin-like growth factor-binding protein 3 lung adenocarcinomas

Clinical Lung Cancer

Volumn 5, Issue 5, 2004, Pages 307-312

  Gharib, Tarek G ^a   Chen, Guoan ^a   Huang, Chiang Ching ^b   Misek, David E ^a   Iannettoni, Mark D ^a   Hanash, Samir M ^a   Orringer, Mark B ^a   Beer, David G ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Hypoxia inducible factor; Microarrays; Non small cell lung cancer; Two dimensional polyacrylamide gel electrophoresis

Indexed keywords

BRADYKININ RECEPTOR; HYPOXIA INDUCIBLE FACTOR 1; ISOPROTEIN; MESSENGER RNA; POLYACRYLAMIDE GEL; SOMATOMEDIN BINDING PROTEIN 3; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA MICROARRAY; FEMALE; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; PROTEOMICS; RNA ANALYSIS; STATISTICAL SIGNIFICANCE; TUMOR DIFFERENTIATION; TWO DIMENSIONAL GEL ELECTROPHORESIS;

EID: 2442530968     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2004.n.011     Document Type: Article

References (39)

1. Niklinska W, Burzykowski T, Chyczewski L, et al. Expression of vascular endothelial growth factor (VEGF) in non-small cell lung cancer (NSCLC): association with p53 gene mutation and prognosis. Lung Cancer 2001; 34:59-64.
2. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9:669-676.
3. Semenza GL. Hypoxia inducible factor 1: oxygen homeostasis and disease pathophysiology. Trends Mol Med 2001; 7:345-350.
4. Subarsky P, Hill RP. The hypoxic tumour microenvironment and metastatic progression. Clin Exp Metastasis 2003; 20:237-250.
5. Semenza GL. Signal transduction to hypoxia-inducible factor 1. Biochem Pharmacol 2002; 64:993-998.
6. Liu C, Lian F, Smith DE, et al. Lycopene supplementation inhibits lung squamous metaplasia and induces apoptosis via up-regulating insulin-like growth factor binding protein 3 in cigarette smoke-exposed ferrets. Cancer Res 2003; 63:3138-3144.
7. Chang YS, Gong K, Sun S, et al. Clinical significance of insulin-like growth factor-binding protein-3 expression in stage I non-small cell lung cancer. Clin Cancer Res 2002; 8:3796-3802.
8. Jaques G, Noll K, Wegmann B, et al. Nuclear localization of insulin-like growth factor binding protein 3 in a lung cancer cell line. Endocrinology 1997; 138:1767-1770.
9. Lee HY, Chun KH, Liu B, et al. Insulin-like growth factor binding protein-3 inhibits the growth of non-small cell lung cancer. Cancer Res 2002; 62:3530-3537.
10. Chang YS, Wang L, Liu D, et al. Correlation between insulin-like growth factor-binding protein-promoter methylation and prognosis of patients with stage I non-small cell lung cancer. Clin Cancer Res 2002; 8:3669-3675.
11. Fry WA, Phillips JL, Menck HR. Ten-year survey of lung cancer treatments and survival in hospitals in the United States. Cancer 1999; 86:1867-1876.
12. Beer DG, Kardia SLR, Huang CC, et al. Gene expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002; 8:816-824.
13. Ma PC, Blaszkowsky L, Bharti A, et al. Circulating tumor cells and serum tumor biomarkers in small cell lung cancer. Anticancer Res 2003; 23:49-62.
14. Minami K, Saito Y, Imamura H, et al. Prognostic significance of p53, ki-67, VEGF and Glut-1 in resecred stage I adenocarcinoma of the lung. Lung Cancer 2002; 38:51-57.
15. Gharib TG, Chen G, Wang H, et al. Proteomic analysis of cytokeratin isoforms uncovers association with survival in lung adenocarcinoma. Neoplasia 2002; 4:440-448.
16. Chen G, Gharib TG, Huang CC, et al. Proteomic analysis of lung adenocarcinoma: identification of a highly expressed set of proteins in tumors. Clin Cancer Res 2002; 8:2298-2305.
17. Chen G, Gharib TG, Huang CC, et al. Discordant protein and mRNA expression in lung adenocarcinomas. Mol Cell Proteomics 2002; 1:304-313.
18. Chen G, Wang H, Gharib TG, et al. Overexpression of oncoprotein 18 correlates with poor differentiation in lung adenocarcinomas. Mol Cell Proteomics 2003; 2:107-116.
19. Chen G, Gharib TG, Thomas DG, et al. Proteomic analysis of eIF-5A in lung adenocarcinomas. Proteomics 2003; 3:496-504.
20. Miller CT, Chen G, Gharib TG, et al. Increased C-CRK proto-oncogene expression is associated with an aggressive phenotype in lung adenocarcinomas. Oncogene 2003; 22:7950-7957.
21. Giordano TJ, Shedden KA, Schwartz DR, et al. Organ-specific molecular classification of primary lung, colon, and ovarian adenocarcinomas using gene expression profiles. Am J Pathol 2001; 159:1231-1238.
22. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001; 98:5116-5121.
23. Frankin SL, Ferry RJ, Cohen P. Rapid insulin-like growth factor (IGF)-independent effects of IGF binding protein-3 on endothelial cell survival. J Clin Endocrinol Metab 2003; 88:900-907.
24. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997; 18:4-25.
25. Dvorak HF, Brown LF, Detmar M, et al. Vascular permeability factor/vascular endothelial growth factor, microvascular permeability, and angiogenesis. Am J Pathol 1995; 146:1029-1039.
26. Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 1994; 79:185-188.
27. Feldser D, Agani F, Iyer NV, et al. Reciprocal positive regulation of hypoxia-inducible factor 1a and insulin-like growth factor 2. Cancer Res 1999; 59:3915-3918.
28. Manes S, Llorente M, Lacalle RA, et al. The matrix metalloproteinase-9 regulates insulin-like growth factor-triggered autocrine response in DU-145 carcinoma cells. J Biol Chem 1999; 274:6935-6945.
29. Krause WF, DuBois RN. The molecular basis for prevention of colorectal cancer. Clin Colorectal Cancer 2001; 1:47-54.
30. Cutler NS, Graves-Deal R, LaFleur BJ, et al. Stromal production of prostacyclin confers an antiapoptic effect to colonic epithelial cells. Cancer Res 2003; 63:1748-1751.
31. Tsubouchi Y, Sano H, Kawahito Y, et al. Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-gamma agonists through induction of apoptosis. Biochem Biophys Res Commun 2000; 270:400-405.
32. Chinnadurai G. CtBP, an unconventional transcriptional in development and oncogenesis. Mol Cell 2002; 9:213-224.
33. Touitou R, Hickabottom M, Parker G, et al. Physical and functional interactions between the corepressor CtBP and the Epstein-Barr virus nuclear antigen EBNA3C. J Viro1 2001; 75:7749-7755.
34. Mirtti T, Alanen K, Kallajoki M, et al. Expression of cystatins, high molecular weight cytokeratin, and proliferation markers in prostatic adenocarcinoma and hyperplasia. Prostate 2003; 54:290-298.
35. Zhang R, Tremblay TL, McDermid A, et al. Identification of differentially expressed proteins in human glioblastoma cell lines and tumors. Glia 2003; 42:194-208.
36. Ebert E, Werle B, Julke B, et al. Expression of cysteine protease inhibitors stefin A, stefin B, and cystatin C in human lung tumor tissue. Adv Exp Med Biol 1997; 421:259-265.
37. Ishihara K, Hayashi I, Yamashina S, et al. A potential role of bradykinin in angiogenesis and growth of S-180 mouse tumors. Jpn J Pharmacol 2001; 87:318-326.
38. Wu J, Akaike T, Hayashida K, et al. Identification of bradykinin receptors in clinical cancer specimens and murine tumor tissues. Int J Cancer 2002; 98:29-35.
39. Chan DC, Gera L, Stewart JM, et al. Bradykinin antagonist dimmer, CU201, inhibits the growth of human lung cancer cell lines in vitro and in vivo and produces synergistic growth inhibition in combination with other antitumor agents. Clin Cancer Res 2002; 8:1280-1287.